Targeted vulnerabilities to overcome drug resistance in breast cancer – EMC2
One of the major challenges in the treatment of breast cancer is the fact that tumors are highly heterogeneous. This variability between and within tumors results in the spread of cancer cells from the primary site to distant sites, a process called metastasis, which represents the most lethal aspect of this disease. To improve therapeutic […]
Collaborative governance of the Réseau de cancérologie du Québec – EMC2
This study has great potential to reduce the burden of cancer on individuals and healthcare systems. People affected by cancer (PTC) receive care from multiple specialties in different locations and numerous simultaneous or delayed interventions. They suffer from professional and organizational silos. The result is undue delays in access, unmet needs, sub-optimal care experience and […]
Therapeutic vulnerability in acute leukemia – EMC2
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and ALL-T accounts for 20% of these cancers, peaking at 2-5 years of age. Although this cancer originates in the thymus, it spreads throughout the body and is rapidly lethal without treatment. Current treatments for T-ALL achieve good survival rates of 90% in children, but […]
Targeting genomic instability as a key vulnerability in ovarian cancer – EMC2
Ovarian cancer is the fifth leading cause of death in North America, and the second most common gynecological cancer. Largely asymptomatic, over 70% of affected patients are diagnosed at an advanced stage of the disease, where the five-year survival rate is around 40%. Ovarian cancer treatment consists of a combination of surgery and chemotherapy. Many […]
Establishing a chemogenomic screening pipeline for high-risk pediatric leukemias – EMC2
In children, acute myeloid leukemia (AML) is a form of blood cancer still associated with very low cure rates. Although less frequent than other pediatric leukemia subtypes, AML is responsible for the majority of deaths in children. AML is a disease composed of various genetic subgroups, some of which are associated with a very poor […]
Optimizing care for patients with castration-resistant prostate cancer – EMC2
Prostate cancer (CaP) is the most common cancer affecting North American men. However, as the cancer progresses, patients no longer respond to the treatments offered, and the cancer will inevitably spread to cause metastases, which are often located in the bones. In order to offer these patients more effective, personalized treatments, we need to be […]
Development of therapeutic vaccines against acute myeloid and lymphoid leukemias – EMC2
Acute leukemia (ALL) is a highly malignant form of blood cancer that affects both children and adults. The fundamental aim is to develop vaccines to treat (rather than prevent) ALL. To achieve this, Dr. Perreault and his team will need to discover antigens present exclusively on leukemia cells and capable of eliciting a strong immune […]